AI Therapeutics

AI Therapeutics was founded in 2013, originally named LAM Therapeutics, with the mission to advance the clinical development of new therapies for lymphangioleiomyomatosis (LAM) and other diseases. In 2018, they renamed to AI Therapeutics. AI Therapeutics collaborates with a dedicated team of experts in science, clinical, and drug development, focusing on pioneering deep learning-based AI to go beyond cancer and rare diseases. It is an AI-driven company with the unique ability to match drugs with indications and prosecute them through clinical development. Our current clinical-stage candidate drugs target several orphan diseases, including pulmonary sarcoidosis, bronchiolitis obliterans post-lung transplant, and amyotrophic lateral sclerosis.